Electromyoneurography and laboratory findings in a case of Guillain-Barré syndrome after second dose of Pfizer COVID-19 vaccine
Roberto Scendoni, Cristina Petrelli, Giorgia Scaloni, Francesco Logullo
Abstract
Guillain-Barre syndrome (GBS) is an acute immune-mediated disease of the peripheral nerves and nerve roots (polyradiculoneuropathy) that is usually elicited by various infections. We present a case of GBS after receiving the second dose of Pfizer-COVID 19 vaccine. Diagnosis was made after performing an accurate clinical examination, electromyoneurography and laboratory tests. In particular, anti-ganglioside antibodies have tested positive. During this pandemic with ongoing worldwide mass vaccination campaign, it is critically important for clinicians to rapidly recognize neurological complications or other side effects associated with COVID-19 vaccination.
Topics & Concepts
Guillain-Barre syndromeMedicinePolyradiculoneuropathyVaccinationCoronavirus disease 2019 (COVID-19)PandemicImmunologyMass vaccinationPediatricsDiseaseInternal medicineInfectious disease (medical specialty)Peripheral Neuropathies and DisordersLong-Term Effects of COVID-19SARS-CoV-2 and COVID-19 Research